Charles Sawyers

Q: What Schools Are Affiliated With Charles Sawyers

Charles Sawyers is affiliated with the following schools: California Institute of Technology, Weill Cornell Medicine, Icahn School of Medicine at Mount Sinai, University of California, Los Angeles, Princeton University, Baylor College of Medicine, University of Massachusetts Medical School, University of Toronto, University of California, San Francisco, Catholic University of Korea, Albert Einstein College of Medicine, Lund University, Johns Hopkins University, Harvard University

Charles Sawyers's AcademicInfluence.com Rankings

Charles Sawyers

Medical

#224

World Rank

#337

Historical Rank

#104

USA Rank

Oncology

#12

World Rank

#13

Historical Rank

USA Rank

medical Degrees

Charles Sawyers

Philosophy

#3244

World Rank

#5286

Historical Rank

#1050

USA Rank

Logic

#1033

World Rank

#1651

Historical Rank

#344

USA Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is Charles Sawyers Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Charles L. Sawyers is a Howard Hughes Medical Institute investigator who holds the Marie-Josée and Henry R. Kravis Chair of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center . HOPP is a program created in 2006 that comprises researchers from many disciplines to bridge clinical and laboratory discoveries.

(See a Problem?)

Charles Sawyers's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The phosphatidylinositol 3-Kinase–AKT pathway in human cancer (2002) (6024)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. (2001) (5035)
Integrative genomic profiling of human prostate cancer. (2010) (3312)
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification (2001) (3189)
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. (2001) (2772)
Integrative Clinical Genomics of Advanced Prostate Cancer (2015) (2458)
Molecular determinants of resistance to antiandrogen therapy (2004) (2298)
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. (2002) (2065)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer (2009) (2012)
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor (2004) (1820)
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. (2002) (1684)
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. (2006) (1648)
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. (2004) (1541)
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. (2005) (1455)
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. (2002) (1196)
Chronic myeloid leukemia. (1999) (1131)
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. (2011) (1075)
Organoid Cultures Derived from Patients with Advanced Prostate Cancer (2014) (1074)
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. (2002) (1068)
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. (2016) (1060)
Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer (2012) (1043)
A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase (1999) (1036)
Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. (2005) (1020)
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR (2001) (1019)
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study (2010) (1004)
Targeted cancer therapy (2004) (979)
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer (2015) (938)
The cancer biomarker problem (2008) (869)
Dynamics of chronic myeloid leukaemia (2005) (818)
Myc-driven murine prostate cancer shares molecular features with human prostate tumors. (2003) (779)
Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade (2013) (769)
A cytoplasmic inhibitor of the JNK signal transduction pathway. (1997) (708)
The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. (1998) (707)
Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. (1998) (698)
Genomic correlates of clinical outcome in advanced prostate cancer (2019) (647)
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer (2017) (638)
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer (2006) (633)
An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice (2001) (616)
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor (2010) (611)
Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance (2017) (598)
Ovarian cancer: screening, treatment, and followup. (1995) (579)
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. (2002) (574)
Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. (2003) (574)
Gene expression changes associated with progression and response in chronic myeloid leukemia. (2006) (570)
Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma (2008) (568)
ARN-509: a novel antiandrogen for prostate cancer treatment. (2012) (557)
Identification of Multipotent Luminal Progenitor Cells in Human Prostate Organoid Cultures (2014) (538)
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. (2005) (532)
The long tail of oncogenic drivers in prostate cancer (2018) (529)
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis (2009) (481)
Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. (2004) (475)
Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. (1996) (468)
Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. (2003) (449)
Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice (1997) (427)
Dominant negative MYC blocks transformation by ABL oncogenes (1992) (418)
Targeting the androgen receptor pathway in prostate cancer. (2008) (416)
Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. (2000) (404)
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. (2007) (401)
The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. (1995) (399)
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR (2011) (397)
Integrative Clinical Genomics of Advanced Prostate Cancer (2015) (383)
Androgen receptor signaling regulates DNA repair in prostate cancers. (2013) (376)
Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade (2019) (364)
Leukemia and the disruption of normal hematopoiesis (1991) (360)
Overcoming mutation-based resistance to antiandrogens with rational drug design (2013) (354)
HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. (2004) (352)
AKT Activity Determines Sensitivity to Mammalian Target of Rapamycin (mTOR) Inhibitors by Regulating Cyclin D1 and c-myc Expression* (2004) (348)
Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain (2006) (345)
Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing (2017) (321)
Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. (1999) (315)
Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. (2005) (314)
Transcriptional regulation of a metastasis suppressor gene by Tip60 and β-catenin complexes (2005) (311)
BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. (2002) (311)
Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. (2017) (309)
Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations (2011) (307)
Copy number alteration burden predicts prostate cancer relapse (2014) (295)
The nuclear tyrosine kinase c-abl negatively regulates cell growth (1994) (292)
Organoid culture systems for prostate epithelial tissue and prostate cancer tissue (2016) (289)
Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene (1995) (288)
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop (2002) (283)
Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. (2006) (274)
Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. (2002) (266)
ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss (2013) (260)
In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). (2001) (257)
Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. (2007) (255)
ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours (2010) (255)
Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen (2011) (255)
Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. (2006) (244)
A rectal cancer organoid platform to study individual responses to chemoradiation (2019) (242)
Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. (2005) (241)
Role for c-Abl tyrosine kinase in growth arrest response to DNA damage (1996) (237)
Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias (2003) (237)
Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. (2013) (234)
Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. (2008) (226)
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. (2008) (223)
Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). (2010) (222)
Mitogen-Activated Protein Kinase Kinase Kinase 1 Activates Androgen Receptor-Dependent Transcription and Apoptosis in Prostate Cancer (1999) (222)
Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation (2002) (214)
Patient derived organoids to model rare prostate cancer phenotypes (2018) (208)
The Survival Function of the Bcr-Abl Oncogene Is Mediated by Bad-Dependent and -Independent Pathways: Roles for Phosphatidylinositol 3-Kinase and Raf (2000) (206)
Differential complementation of Bcr-Abl point mutants with c-Myc. (1994) (205)
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. (2011) (203)
Will mTOR inhibitors make it as cancer drugs? (2003) (194)
Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. (2012) (187)
Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ. (2015) (186)
Survival signaling mediated by c-Jun NH2-terminal kinase in transformed B lymphoblasts (2002) (177)
The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. (2008) (177)
Lineage plasticity in cancer: a shared pathway of therapeutic resistance (2020) (177)
A federated ecosystem for sharing genomic, clinical data (2016) (177)
Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer (2007) (176)
Opportunities and challenges in the development of kinase inhibitor therapy for cancer. (2003) (176)
Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. (2009) (174)
NF-κB Activates Prostate-Specific Antigen Expression and Is Upregulated in Androgen-Independent Prostate Cancer (2002) (174)
Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. (2007) (171)
Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death (2018) (169)
Cooperative Assembly of Androgen Receptor into a Nucleoprotein Complex That Regulates the Prostate-specific Antigen Enhancer* (1999) (166)
A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. (2008) (164)
Converting Cancer Therapies into Cures: Lessons from Infectious Diseases (2012) (161)
C/EBPalpha bypasses granulocyte colony-stimulating factor signals to rapidly induce PU.1 gene expression, stimulate granulocytic differentiation, and limit proliferation in 32D cl3 myeloblasts. (1999) (154)
Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants (2006) (150)
CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma (2014) (150)
Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. (2009) (149)
The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance (2019) (149)
The CRKL Adaptor Protein Transforms Fibroblasts and Functions in Transformation by the BCR-ABL Oncogene* (1996) (144)
SPOP mutations in prostate cancer across demographically diverse patient cohorts. (2014) (143)
Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. (2005) (140)
Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction. (1990) (138)
p53 dependent growth suppression by the c-Abl nuclear tyrosine kinase. (1995) (136)
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer (2018) (135)
FOXA1 mutations alter pioneering activity, differentiation, and prostate cancer phenotypes (2019) (128)
Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer (2017) (127)
Rational therapeutic intervention in cancer: kinases as drug targets. (2002) (125)
Regenerative potential of prostate luminal cells revealed by single-cell analysis (2020) (121)
Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. (2002) (121)
Interleukin-6-induced inhibition of multiple myeloma cell apoptosis: support for the hypothesis that protection is mediated via inhibition of the JNK/SAPK pathway. (1998) (120)
Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia (2002) (119)
Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. (2002) (113)
C/EBP Bypasses Granulocyte Colony-Stimulating Factor Signals to Rapidly Induce PU.1 Gene Expression, Stimulate Granulocytic Differentiation, and Limit Proliferation in 32D cl3 Myeloblasts (1999) (112)
Mutations in the mitotic check point gene, MAD1L1, in human cancers (2001) (112)
Signal transduction by wild-type and leukemogenic Abl proteins. (1997) (111)
A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. (2003) (111)
Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET. (2005) (110)
Identification of an oncogenic RAB protein (2015) (109)
Propagation of human blastic myeloid leukemias in the SCID mouse. (1992) (109)
Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. (2018) (103)
Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation. (2015) (98)
Chronic myelomonocytic leukemia: Tel-a-kinase what Ets all about (1994) (96)
Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer (2020) (94)
JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate (2012) (92)
Shifting paradigms: the seeds of oncogene addiction (2009) (88)
NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. (2002) (85)
Structural Requirements for Function of the Crkl Adapter Protein in Fibroblasts and Hematopoietic Cells (1998) (84)
β4 Integrin signaling induces expansion of prostate tumor progenitors. (2013) (84)
Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. (2002) (83)
MYC Cooperates with AKT in Prostate Tumorigenesis and Alters Sensitivity to mTOR Inhibitors (2011) (82)
Low CD38 Identifies Progenitor-like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome (2016) (82)
Four Years of Follow-Up of 1027 Patients with Late Chronic Phase (L-CP), Accelerated Phase (AP), or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Treated with Imatinib in Three Large Phase II Trials. (2004) (82)
Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. (2006) (81)
Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells. (2006) (79)
TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells (2002) (79)
Signal transduction pathways involved in BCR-ABL transformation. (1997) (78)
Facilitating a culture of responsible and effective sharing of cancer genome data (2016) (75)
Genotoxic Drugs Induce Interaction of the c-Abl Tyrosine Kinase and the Tumor Suppressor Protein p53* (1996) (73)
Production of granulocyte‐macrophage colony‐stimulating factor in two patients with lung cancer, leukocytosis, and eosinophilia (1992) (72)
Positron Emission Tomography/Computed Tomography–Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer (2017) (72)
Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation (2020) (68)
Whole-body skeletal imaging in mice utilizing microPET: optimization of reproducibility and applications in animal models of bone disease (2002) (66)
ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis (2017) (64)
Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. (2012) (64)
Annotating MYC oncogene status with 89Zr-transferrin imaging (2012) (63)
Antibody-Based Profiling of the Phosphoinositide 3-Kinase Pathway in Clinical Prostate Cancer (2004) (63)
Fitness Conferred by BCR-ABL Kinase Domain Mutations Determines the Risk of Pre-Existing Resistance in Chronic Myeloid Leukemia (2011) (62)
Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics. (2002) (61)
SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance (2018) (61)
Drug discovery: How melanomas bypass new therapy (2010) (59)
A HIF-Regulated VHL-PTP1B-Src Signaling Axis Identifies a Therapeutic Target in Renal Cell Carcinoma (2011) (59)
Cancer: Mixing cocktails (2007) (58)
AACR Cancer Progress Report 2013 (2013) (58)
New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia. (1997) (57)
Mechanistic Concepts in Androgen-dependence of Prostate Cancer (2004) (56)
PHA-739358, an Aurora Kinase Inhibitor, Induces Clinical Responses in Chronic Myeloid Leukemia Harboring T315I Mutations of BCR-ABL. (2007) (56)
Imatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor. (2002) (56)
Amplification and overexpression of prosaposin in prostate cancer (2005) (54)
Functional role for the c-Abl tyrosine kinase in meiosis I (1998) (53)
Chromosomal aberrations in prostate cancer xenografts detected by comparative genomic hybridization (2002) (52)
Development of an animal model for prostate cancer cell metastasis to adult human bone. (2001) (52)
Interferon-α induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo (2002) (51)
Hematologic and Cytogenetic Responses in Imatinib-Resistant Chronic Phase Chronic Myeloid Leukemia Patients Treated with the Dual SRC/ABL Kinase Inhibitor BMS-354825: Results from a Phase I Dose Escalation Study. (2004) (51)
ETV1 is a lineage-specific survival factor in GIST and cooperates with KIT in oncogenesis (2010) (47)
Identification of Different Classes of Luminal Progenitor Cells within Prostate Tumors. (2015) (47)
All the World's a Stage: Facilitating Discovery Science and Improved Cancer Care through the Global Alliance for Genomics and Health. (2015) (45)
Molecular genetics of acute leukaemia (1997) (43)
Research on Resistance to Cancer Drug Gleevec (2001) (42)
The role of myc in transformation by BCR-ABL. (1993) (41)
Will kinase inhibitors have a dark side? (2006) (41)
MAGI-2 scaffold protein is critical for kidney barrier function (2014) (40)
A phase I study of BMS-354825 in patients with imatinib-resistant and intolerant chronic phase chronic myeloid leukemia (CML): Results from CA180002 (2005) (39)
Defining a common region of deletion at 13q21 in human cancers (2001) (39)
Interferon-alpha induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo. (2002) (37)
Sharing Clinical and Genomic Data on Cancer - The Need for Global Solutions. (2017) (37)
A phase I study of BMS-354825 in patients with imatinib-resistant and intolerant accelerated and blast phase chronic myeloid leukemia (CML): Results from CA180002 (2005) (36)
Molecular consequences of the BCR-ABL translocation in chronic myelogenous leukemia. (1993) (36)
In vitro modulation of the invasive and metastatic potentials of human renal cell carcinoma by interleukin‐2 and/or interferon‐alpha gene transfer (1994) (35)
Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model (2010) (34)
Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements (2007) (33)
AACR Cancer Progress Report 2012 (2012) (33)
Tyrosine kinase inhibitors in chronic myeloid leukemia. (1999) (33)
Imaging Tumor Burden in the Brain with 89Zr-Transferrin (2013) (33)
Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors. (2011) (33)
"N of 1" case reports in the era of whole-genome sequencing. (2013) (33)
Making progress through molecular attacks on cancer. (2005) (32)
Epithelial Smad4 Deletion Up-Regulates Inflammation and Promotes Inflammation-Associated Cancer (2018) (31)
MicroPET imaging of prostate cancer in LNCAP‐SR39TK‐GFP mouse xenografts (2003) (30)
FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer. (2020) (30)
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. (2018) (30)
Developing Standards for Breakthrough Therapy Designation in Oncology (2013) (29)
Identifying Actionable Targets through Integrative Analyses of GEM Model and Human Prostate Cancer Genomic Profiling (2014) (28)
c-Abl is required for development and optimal cell proliferation in the context of p53 deficiency. (2000) (28)
Phase I/II study of MDV3100 in patients (pts) with progressive castration-resistant prostate cancer (CRPC) (2008) (28)
Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling (2022) (28)
Identification of a pseudogene that can masquerade as a mutant allele of the PTEN/MMAC1 tumor suppressor gene. (1998) (27)
IκB kinase β inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells (2008) (27)
Modulators of Prostate Cancer Cell Proliferation and Viability Identified by Short-Hairpin RNA Library Screening (2012) (27)
Somatic tissue engineering in mouse models reveals an actionable role for WNT pathway alterations in prostate cancer metastasis. (2020) (27)
Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia in first remission (1997) (26)
Even better kinase inhibitors for chronic myeloid leukemia. (2010) (26)
Efficacy of Dasatinib in Patients with Chronic Phase Philadelphia Chromosome-Positive CML Resistant or Intolerant to Imatinib: First Results of the CA180013 ‘START-C’ Phase II Study. (2005) (26)
Treating Imatinib-Resistant Leukemia: The Next Generation Targeted Therapies (2006) (26)
Calculated resistance in cancer (2005) (25)
The emergence of resistance to targeted cancer therapeutics. (2002) (25)
Modulation of androgen receptor DNA binding activity through direct interaction with the ETS transcription factor ERG (2020) (25)
Characteristics and outcome of AKT1 E17K-mutant breast cancer defined through AACR GENIE, a clinicogenomic registry. (2020) (24)
Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. (2001) (24)
A Phase II Study of Dasatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Crisis Who Are Resistant or Intolerant to Imatinib: First Results of the CA180006 ‘START-B’ Study. (2005) (24)
Cross-species comparisons of cancer signaling (2005) (24)
Dasatinib (BMS-354825) in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib: Update of a Phase I Study. (2005) (23)
Chronic myelogenous leukemia. (2001) (23)
Transgenic mouse model for rapid pharmacodynamic evaluation of antiandrogens. (2006) (23)
Comprehensive mutational analysis and mRNA isoform quantification of TP63 in normal and neoplastic human prostate cells (2009) (22)
Challenges in validating candidate therapeutic targets in cancer (2018) (22)
American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange: From Inception to First Data Release and Beyond—Lessons Learned and Member Institutions’ Perspectives (2018) (22)
Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer. (2020) (20)
Significance of residual leukaemia transcripts after bone marrow transplant for CML (1990) (20)
Tumor mutational landscape is a record of the pre-malignant state (2019) (20)
Reliable and Effective Diagnostics Are Keys to Accelerating Personalized Cancer Medicine and Transforming Cancer Care: A Policy Statement from the American Association for Cancer Research (2014) (19)
A Tmprss2-CreERT2 Knock-In Mouse Model for Cancer Genetic Studies on Prostate and Colon (2016) (19)
Dasatinib (D) in patients (pts) with chronic myelogenous leukemia (CML) in myeloid blast crisis (MBC) who are imatinib-resistant (IM-R) or IM-intolerant (IM-I): Results of the CA180006 'START-B' study. (2006) (19)
In cancer drug resistance, germline matters too (2012) (19)
Traversing the genomic landscape of prostate cancer from diagnosis to death (2012) (18)
Isolation of unknown genes from human bone marrow by differential screening and single-pass cDNA sequence determination. (1994) (17)
Perspective: Combined forces (2013) (17)
Coordinate transcriptional regulation by ERG and androgen receptor in fusion-positive prostate cancers. (2010) (17)
GREB1 amplifies androgen receptor output in human prostate cancer and contributes to antiandrogen resistance (2019) (17)
Five Year Follow-Up Results of a Phase II Trial in Patients with Late Chronic Phase (L-CP) Chronic Myeloid Leukemia (CML) Treated with Imatinib Who Are Refractory/Intolerant of Interferon-α. (2005) (17)
Herceptin: A First Assault on Oncogenes that Launched a Revolution (2019) (17)
Deletion of 3p13-14 locus spanning FOXP1 to SHQ1 cooperates with PTEN loss in prostate oncogenesis (2017) (16)
Finding and Drugging the Vulnerabilities of RAS-Dependent Cancers (2009) (15)
Cancer treatment in the STI571 era: what will change? (2001) (15)
TORward AKTually useful mouse models (2004) (15)
Transplantation of IL-2-mobilized autologous peripheral blood progenitor cells for adults with acute myelogenous leukemia in first remission (2001) (15)
Integrative Clinical Genomics of Advanced Prostate Cancer Graphical (2015) (14)
Xenograft Models and the Molecular Biology of Human Prostate Cancer (2001) (14)
Microsatellite instability in prostate cancer and response to immune checkpoint blockade. (2018) (14)
Visualization of the Interstitial Cells of Cajal (ICC) Network in Mice (2011) (14)
Molecular Analysis of Dasatinib Resistance Mechanisms in CML Patients Identifies Novel BCR-ABL Mutations Predicted To Retain Sensitivity to Imatinib: Rationale for Combination Tyrosine Kinase Inhibitor Therapy. (2005) (14)
Molecular Oncology: Causes of Cancer and Targets for Treatment (2013) (14)
Applying 89Zr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins (2016) (14)
Molecular abnormalities in myeloid leukemias and myelodysplastic syndromes. (1998) (14)
Correlation of clinical response to BMS-354825 with BCR-ABL mutation status in imatinib-resistant patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-associated acute lymphoblastic leukemia (Ph+ ALL) (2005) (12)
The 2011 Gordon Wilson Lecture: overcoming resistance to targeted cancer drugs. (2012) (12)
CD38 in Advanced Prostate Cancers (2021) (12)
Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses. (2019) (12)
Where lies the blame for resistance—tumor or host? (2007) (12)
The bcr-abl gene in chronic myelogenous leukaemia. (1992) (11)
Potent Transient Inhibition of BCR-ABL by Dasatinib Leads to Complete Cytogenetic Remissions in Patients with Chronic Myeloid Leukemia: Implications for Patient Management and Drug Development. (2006) (11)
Translational research: are we on the right track? 2008 American Society for Clinical Investigation Presidential Address. (2008) (11)
Signal transduction-based strategies for the treatment of chronic myelogenous leukemia. (1996) (11)
Sequential Kinase Inhibitor Therapy in CML Patients Can Select for Cells Harboring Compound BCR-ABL Kinase Domain Mutations with Increased Oncogenic Potency: Rationale for Early Combination Therapy of ABL Kinase Inhibitors. (2006) (10)
Disruption of MAGI2-RapGEF2-Rap1 signaling contributes to podocyte dysfunction in congenital nephrotic syndrome caused by mutations in MAGI2. (2019) (10)
Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers (2021) (10)
Towards a global cancer knowledge network: dissecting the current international cancer genomic sequencing landscape (2017) (9)
Increased expression of androgen receptor (AR) and enzymes involved in androgen synthesis in metastatic prostate cancer: Targets for novel personalized therapies. (2009) (8)
GENETIC APPROACHES TO DEFINING SIGNALING BY THE CML-ASSOCIATED TYROSINE KINASE BCR-ABL (1994) (8)
The Most Common Dasatinib-Resistant BCR-ABL Kinase Domain Mutations in Patients with Chronic Myeloid Leukemia Are Sensitive to VX-680: Rationale for Early Combination Kinase Inhibitor Therapy. (2006) (8)
Resistance to imatinib: more and more mutations (2003) (8)
Rapid interrogation of cancer cell of origin through CRISPR editing (2021) (8)
BMS-354825 Is a SRC/ABL Inhibitor with High Nanomolar Activity Against the Kit D816v Mutation, Which Drives Systemic Mastocytosis and Is Imatinib-Resistant. (2004) (8)
Cabozantinib Resolves Bone Scans in Tumor-Naïve Mice Harboring Skeletal Injuries (2014) (7)
A first-in-human, open-label, phase I/II safety, pharmacokinetic, and proof-of-concept study of ARN-509 in patients with progressive advanced castration-resistant prostate cancer (CRPC). (2011) (7)
Pha-739358: a pan-aurora kinase inhibitor (2009) (7)
Oncogenic ERG Represses PI3K Signaling through Downregulation of IRS2 (2020) (7)
Towards a global cancer knowledge network: dissecting the current international cancer genomic sequencing landscape (2017) (7)
Gene Expression Signatures Associated with Treatment and Resistance to Imatinib Mesylate in Chronic Myeloid Leukemia Patients. (2005) (7)
Allosteric interactions prime androgen receptor dimerization and activation (2022) (6)
Long-Term Efficacy of Dasatinib in Chronic-Phase CML: Results from the Phase I Trial (CA180002). (2007) (6)
Advances in Brief A Novel Pyridopyrimidine Inhibitor of Abl Kinase Is a Picomolar Inhibitor of Bcr-abl-driven K 562 Cells and Is Effective against STI 571-resistant Bcr-abl Mutants 1 (2003) (6)
Allosteric interactions prime androgen receptor dimerization and activation. (2022) (6)
FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes (2019) (5)
Circulating tumor cells (CTC) and prostate specific antigen (PSA) as response indicator biomarkers in chemotherapy-naïve patients with progressive castration-resistant prostate cancer (CRPC) treated with MDV3100. (2010) (5)
Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with secondary acute myelogenous leukemia in first remission. (1999) (5)
Publisher Correction: The long tail of oncogenic drivers in prostate cancer (2019) (5)
Major Molecular Responses to Dasatinib (BMS-354825) Are Observed in Imatinib-Resistant Late Stage Chronic and Advanced CML Patients: Impact and Fate of Imatinib-Resistant Clones in Dasatinib-Treated Patients. (2005) (5)
Recent success with the tyrosine kinase inhibitor STI-571--lessons for targeted therapy of cancer. (2001) (5)
Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib. (2010) (5)
Targeting DNA Repair in Prostate Cancer. (2018) (5)
Good Prognosis of CML Patients with Clonal Cytogenetic Abnormalities in Ph-Negative Cells. (2005) (5)
Author response: Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer (2017) (4)
Author response: Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death (2018) (4)
Major Cytogenetic Responses to BMS-354825 in Patients with Chronic Myeloid Leukemia Are Associated with a One to Two Log Reduction in BCR-ABL Transcript. (2004) (4)
The imperative to invest in science has never been greater. (2014) (4)
Determining barriers to effective data sharing in cancer genomic sequencing initiatives: A Global Alliance for Genomics and Health (GA4GH) survey. (2016) (4)
Erratum: Myc-driven murine prostate cancer shares molecular features with human prostate tumors (Cancer Cell (September 2003) 4 (223-238)) (2005) (4)
Abstract LB-103: Landscape of somatic ERBB2 Mutations: Findings from AACR GENIE and comparison to ongoing ERBB2 mutant basket study (2017) (4)
Understanding Drug Sensitivity and Tackling Resistance in Cancer (2022) (4)
Overview: the art of cancer drug screening: molecular target versus milieu-based screens. (2002) (3)
Abstract P3-04-01: Whole transcriptome analysis of AR+ ER/PR- metastatic breast cancers treated with bicalutamide on TBCRC011 (2015) (3)
Comparative Analysis of Two BCR-ABL Small Molecule Inhibitors Reveals Overlapping but Distinct Mechanisms of Resistance. (2004) (3)
Genetic approaches to defining signaling by the CML-associated tyrosine kinase BCR-ABL. (1994) (3)
Strategies to Identify and Target Cells of Origin in Prostate Cancer. (2018) (3)
Effects of Adaphostin, a Novel Tyrphostin Inhibitor, in Diverse Models of Imatinib Mesylate Resistance. (2004) (3)
Abstract 4774: The antitumor effects of PI3K beta inhibitors in PTEN negative prostate cancer are enhanced by inhibition of reactivated PI3K alpha signaling (2014) (3)
Lessons learned from the development of kinase inhibitors. (2009) (3)
Update on the use of imatinib mesylate. (2005) (3)
SMAD4 loss in colorectal cancer: Correlation with recurrence, chemoresistance, and immune infiltrate. (2017) (3)
A rectal cancer model establishes a platform to study individual responses to chemoradiation (2019) (3)
Prospective Clinical Genomic Profiling of Ewing Sarcoma: ERF and FGFR1 Mutations as Recurrent Secondary Alterations of Potential Biologic and Therapeutic Relevance (2022) (2)
Nineteenth Annual Pezcoller Symposium: hypothesis-driven clinical investigation in cancer. (2007) (2)
Six Year Follow-Up Results of a Phase II Study of Imatinib in Late Chronic Phase (L-CP) Chronic Myeloid Leukemia (CML) Post Interferon-A (IFN) Refractoriness/Intolerance. (2006) (2)
Genomic analysis of circulating tumor cells to evaluate predictive biomarkers. (2011) (2)
Clonal Hematopoiesis in Philadelphia Chromosome-Negative Bone Marrow Cells of Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitors (2008) (2)
Growth Inhibitory Effects of the Dual ErbB 1 / ErbB 2 Tyrosine Kinase Inhibitor PKI-166 on Human Prostate Cancer Xenografts 1 (2002) (2)
Multilineage plasticity in prostate cancer through expansion of stem–like luminal epithelial cells with elevated inflammatory signaling (2021) (2)
Abstract 5287: Heterogeneity of mutation calling and annotation: a survey of cancer next-generation sequencing initiatives by the Global Alliance for Genomics and Health (GA4GH): (2016) (2)
Comprar Molecular Oncology. Causes Of Cancer And Targets For Treatment | Gelmann, E. | 9780521876629 | Cambridge University Press (2013) (2)
Philadelphia chromosome-positive acute lymphoid leukemias A phase 2 study of imatinib in patients with relapsed or refractory (2009) (2)
Investigation of a frequently mutated transcriptional repressor in prostate cancer, in particular its role in modulating androgen signaling and its effects on TMPRSS2-ERG dependent tumor maintenance. (2016) (1)
The immunomodulatory protein Dickkopf-1 (DKK1) defines a non-neuroendocrine subtype of metastatic castration-resistant prostate cancer (mCRPC) with low AR and low PSA expression. (2017) (1)
The long tail of significantly mutated genes in prostate cancer. (2017) (1)
SPOP Mutations in Prostate Cancer across Demographically (2014) (1)
Molecular requirements for rapid plasmacytoma and Pre‐B lymphoma induction by abelson murine leukemia virus in myc‐transgenic mice (1994) (1)
Genomic heterogeneity of circulating tumor cells in castration-resistant prostate cancer (CRPC) revealed by single-cell sequencing. (2013) (1)
Therapeutic Kinase Inhibitors (2012) (1)
Abstract 976: FOXA1 promotes a luminal growth program in prostate cancer (2018) (1)
Treating nonhematologic disorders with hematologic stem cells: can this work? (2001) (1)
Abstract LB-102: Landscape analysis of the initial data release from AACR Project GENIE (2017) (1)
CLINICAL STUDY OF MDV3100 IN PROGRESSIVE CASTRATION-RESISTANT PROSTATE CANCER (CRPC) (2009) (1)
JNK/SAPK Pathway the Support for the Hypothesis That Protection Is Mediated Via Inhibition of Induced Inhibition of Multiple Myeloma Cell Apoptosis: - Interleukin-6 (2011) (1)
The long tail of oncogenic drivers in prostate cancer (2018) (1)
Cabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries. (2014) (1)
Linked Entity Attribute Pair (LEAP): A Harmonization Framework for Data Pooling (2020) (1)
Signal Transduction in Prostate Cancer (2002) (1)
Something lost--something gained: the ASCI begins its second century. (2008) (1)
Macrophages promote anti-androgen resistance in prostate cancer bone disease (2023) (1)
Reversal of lineage plasticity in RB1/TP53-deleted prostate cancer through FGFR and Janus kinase inhibition (2021) (1)
Abstract 4292: Frequent detection of xenotropic murine leukemia virus (XMLV) strains including XMRV in human cultures established from mouse xenografts (2011) (1)
Detection of glucocorticoid receptor (GR) expression in circulating tumor cells (CTCs) from patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (2016) (1)
hepatocellular carcinoma CDK 9-mediated transcription elongation is required for MYC addiction Material Supplemental (2014) (1)
Targeted therapy for the treatment of imatinib‐resistant chronic myeloid leukemia: A pharmacogenetic analysis (2005) (1)
Publisher Correction: Lineage plasticity in cancer: a shared pathway of therapeutic resistance (2020) (1)
Abstract A25: Activating alterations of p110 subunits determine PI3K isoform selectivity in prostate cancer (2020) (1)
Implications of signal transduction inhibition for the treatment of chronic myeloid leukemia. (2001) (1)
Low CD 38 Identifies Proge nitor-like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome Graphical Abstract Highlights (2016) (0)
Molecular and Cellular Pathobiology Distinct Patterns of Dysregulated Expression of Enzymes Involved inAndrogenSynthesis andMetabolism inMetastatic Prostate Cancer Tumors (2012) (0)
Imaging Androgen Receptor Signaling in Prostate Cancer with PET (2015) (0)
Molecular Oncology: Preface (2013) (0)
Werner syndrome: association of premature aging and cancer predisposition (2013) (0)
Isolation of Genes Involved in Human Prostate Cancer Progression by Functional Expression Cloning (2001) (0)
SUPPLEMENTARY MATERIAL: FITNESS CONFERRED BY BCR-ABL KINASE DOMAIN MUTATIONS DETERMINES THE RISK OF PRE-EXISTING RESISTANCE IN CHRONIC MYELOID LEUKEMIA (2012) (0)
Deletion of 3p13-14 locus spanning FOXP1 to SHQ1 cooperates with PTEN loss in prostate oncogenesis (2017) (0)
Abstract LB-018: Loss of function mutations of an ETS repressor expand the ETS positive subset of prostate cancer (2016) (0)
The application of high-throughput analyses to cancer diagnosis and prognosis (2013) (0)
Abstract B063: Polyethnic-1000: Advancing cancer genomics by studying ethnically diverse, underserved patient populations in New York (2020) (0)
The tyrosine kinase inhibitor Cabozantinib resolves bone scans in mice with tibial fractures. (2015) (0)
Abstract LB-203: Phase I/II study of the androgen receptor antagonist MDV3100 in castration-resistant prostate cancer (2008) (0)
A TYPE II TRANSMEMBRANE GLYCOPROTEIN ASSOCIATED WITH OSTEOGENESIS CAN ACCELERATE ANDROGEN-INDEPENDENT PROSTATE CANCER PROGRESSION IN VIVO (1999) (0)
ALK: Anaplastic lymphoma kinase (2013) (0)
Abstract IA22: Molecular Imaging of androgen receptor signalling in CRPC (2012) (0)
160 POSTER Phase I-II study of MDV3100 in castration resistant prostate cancer. The Prostate Cancer Clinical Trials Consortium (2008) (0)
Genetic interactions between c-Abl and p53: The role of c-Abl in viability and cell growth (1999) (0)
GREB1 amplifies androgen receptor output in prostate cancer and contributes to antiandrogen resistance (2018) (0)
Abstract 2727: The premalignant state captured in the landscape of somatic mutations can reveal the cancer cell-of-origin (2019) (0)
315 Molecular signature of the PTEN tumor suppressor-identification of IGFBP2 as a surrogate marker for PTEN/Akt signaling (2004) (0)
Effect of the novel anti-androgen ARN-509 on response and seizure in castration-resistant prostate cancer models. (2011) (0)
Abstract 1537: 3p13-14FOXP1-SHQ1deletion spanning multiple potential tumor suppressor genes cooperates withPTENloss in cancer (2017) (0)
Abstract 5128: Polyethnic-1000: Advancing cancer genomics by studying ethnically diverse, underserved patient populations in New York (2019) (0)
Abstract C16: Targeting AR in castration-resistant prostate cancer: Development of ARN-509 and second-generation antiandrogen resistance models (2012) (0)
Abstract LB-070: Next generation sequencing of prostate cancer reveals germline and somatic alterations detected at diagnosis and at metastasis that may impact clinical decision making (2016) (0)
Dynamics of Chronic Myeloid Leukemia Supplementary Online Material (2005) (0)
Abstract 1594: Reversal of lineage plasticity in RB1/TP53-deleted prostate cancer through FGFR and Janus kinase inhibition (2022) (0)
Abstract 3566: The long tail of significantly mutated genes in prostate cancer (2017) (0)
mutation-dependent and -independent imatinib resistance Adaphostin-induced oxidative stress overcomes BCR/ABL (2013) (0)
Abstract 1832: Large variations in clinical and ethical aspects of genomic sequencing initiatives: A Global Alliance for Genomics and Health (GA4GH) survey (2016) (0)
Structural studies of an androgen receptor complex reveal modes of allosteric regulation (2022) (0)
MP31-01 DEVELOPMENT OF NOVEL METASTATIC PROSTATE CANCER CELL LINES BY “ORGANOID” IN VITRO CULTURE TECHNOLOGY (2014) (0)
Transgenic Models for Prostate Cancer (2002) (0)
Target in Renal Cell Carcinoma A HIF-Regulated VHL-PTP 1 B-Src Signaling Axis Identifies a Therapeutic (2011) (0)
Erratum: Position statement, association of American physicians the imperative to invest in science has never been greater (Journal of Clinical Investigation (2014) 124:11 (5085) DOI:10.1172/JCI79469) (2014) (0)
The MYC oncogene family in human cancer (2013) (0)
Abstract PO-134: Identification of the cells of origin and tumor heterogeneity in neuroendocrine prostate cancer (NEPC) by single-cell analysis (2020) (0)
Effect of Janus kinase (JAK) signaling inhibition on lineage plasticity and drug sensitivity in castrate resistant prostate cancer. (2023) (0)
Methods and materials for the evaluation of prostate cancer therapies (2004) (0)
Molecular Biology of Novel Targets Identified Through Study of Castration-Recurrent Prostate Cancer (2009) (0)
Author response: GREB1 amplifies androgen receptor output in human prostate cancer and contributes to antiandrogen resistance (2018) (0)
Positive and Negative Growth Effects of Abl Genes (1995) (0)
Pediatric solid tumors: embryonal cell oncogenesis (2013) (0)
415: Mutational Analysis of the P63 Gene in Prostate Cancer Cells (2004) (0)
Abstract 391: Identifying molecular drivers of olaparib resistance through genome-wide sgRNA screening in prostate organoids (2022) (0)
Resource Integrative Clinical Genomics of Advanced Prostate Cancer (2016) (0)
Abstract 2048: Mutations in FOXA1 alter chromatin remodeling and cell fate in prostate organoids (2023) (0)
Author Correction: FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes (2020) (0)
Abstract 111: Tumor microenvironment derived NRG1 promotes antiandrogen resistance in prostate cancer (2019) (0)
Abstract PL04-01: Overcoming cancer drug resistance (2012) (0)
Abstract PO-117: CHD1-loss promotes tumor heterogeneity and therapy resistance in prostate cancer (2020) (0)
Sanjiv “Sam” Gambhir, MD, PhD: In Memoriam (1962–2020) (2020) (0)
Abstract A072: Polyethnic-1000: Advancing cancer genomics by studying ethnically diverse, underserved patient populations in New York (2020) (0)
Bcr-abl kinase inhibition as the basis of therapy for cml (2000) (0)
Oncogenic events and therapeutic targets in thyroid cancer (2013) (0)
Development of novel metastatic prostate cancer cell lines by “organoid” in vitro culture technology. (2014) (0)
Abstract CN02-03: Circulating tumor cells as biomarkers in the development of the androgen receptor antagonist, MDV3100 (2009) (0)
Abstract IA15: Context-specific oncogenesis by ETS-family transcription factors (2012) (0)
Abstract 2328: Polyethnic-1000: Advancing cancer genomics by studying ethnically diverse, underserved patient populations in New York (2020) (0)
following imatinib mesylate treatment myelogenous leukemia patients in complete cytogenetic remission Persistence of malignant hematopoietic progenitors in chronic (2013) (0)
Abstract 238: Androgen insensitivity syndrome germline loss-of-function mutations in the androgen receptor that acquire somatic gain-of-function in prostate cancer (2016) (0)
Abstract NG06: CHD1-loss confers AR targeted therapy resistance via promoting cancer heterogeneity and lineage plasticity (2020) (0)
Abstract 3430: The protein phosphatase 4 complex is a tumor suppressor in prostate cancer (2020) (0)
Methods and materials for examining vias associated with the progression of glioblastoma. (2003) (0)
Development of antiandrogen ARN-509 1 ARN-509 : a novel antiandrogen for prostate cancer treatment (2012) (0)
Abstract B207: Prostate specific membrane antigen is a diagnostic marker of response to allosteric androgen receptor inhibition (2009) (0)
Molecular Oncology: Chronic myeloid leukemia: imatinib and next-generation ABL inhibitors (2013) (0)
Molecular oncology of acute promyelocytic leukemia (APL) (2013) (0)
Abstract 2244: SPOP mutations in prostate cancer across demographically diverse patient cohorts (2014) (0)
Sigea traesduc io a+based strategies chrer ic for the treat e t myelogeno s eukemia (1996) (0)
Abstract 4165:SOX2promotes lineage plasticity and antiandrogen resistance inTP53andRB1deficient prostate cancer (2017) (0)
An immunocompetent rectal cancer model to study radiation therapy (2022) (0)
Abstract LB-276: The identification and characterization of prostate adenocarcinoma tumor initiating cells (2016) (0)
MP41-06 SPOP MUTATIONS IN PROSTATE CANCER ACROSS DEMOGRAPHICALLY DIVERSE PATIENT COHORTS. (2014) (0)
Lineage plasticity in prostate cancer depends on FGFR and JAK/STAT inflammatory signaling (2022) (0)
Targeting reciprocal feedback inhibition in the clinic: ARN509 and PI3K pathway inhibition in patients with metastatic castration-resistant prostate cancer (mCRPC). (2014) (0)
Abstract IA4: Outcome prediction from the pattern of aberrations in prostate cancer genomes (2012) (0)
Abstract PR3: The snoRNP assembly factor SHQ1 is a novel prostate cancer tumor suppressor gene (2012) (0)
Abstract C037: Polyethnic-1000: A New York-based initiative to advance cancer genomics through recruitment of diverse racial & ethnic populations (2023) (0)
A distinct epigenetic state sensitizes enzalutamide-resistant prostate cancer cells to BET bromodomain inhibition (2016) (0)
(2019). Disruption of MAGI2-RapGEF2-Rap1 signaling contributes to podocyte dysfunction in congenital nephrotic syndrome caused by mutations in MAGI2. Kidney (3), 642-655. (2019) (0)
Altered Oncogenic Fitness of Imatinib- and Dasatinib-Resistant BCR-ABL Mutants Is Due to Differential Intrinsic Kinase Activity and Signaling Pathway Selection Defined by Phosphoproteome Profiling. (2005) (0)
Bristol-Myers Squibb Announces Awards (2004) (0)
Abstract LB-A24: Molecular alteration of SMAD4 in hindgut-derived colorectal tumors identifies a distinct subset of patients and is associated with worse recurrence-free survival (2015) (0)
Patient derived organoids to model rare prostate cancer phenotypes (2018) (0)
Author Correction: Transcriptional regulation of a metastasis suppressor gene by Tip60 and β-catenin complexes (2022) (0)
Cancer drug development. Preface. (2012) (0)
Abstract IA10: Overcoming castration-resistant prostate cancer (2012) (0)
Abstract 1728: Single cell RNA-seq analysis reveals a role of pro-inflammatory tumor-associated macrophages in driving prostate cancer progression (2022) (0)
Imatinib-Resistant BCR-ABL Mutations Alter Oncogenic Potency, Kinase Activity and Substrate Selection. (2004) (0)
chronic myelogenous leukemia patients: 14 months' experience treated - Hematopathologic and cytogenetic findings in imatinib mesylate (2013) (0)
Abstract 5722: Acquired stemness by luminal cells (2020) (0)
Abstract IA22: Reflections on precision medicine (2016) (0)
Rap1 signaling contributes to podocyte dysfunction in congenital nephrotic syndrome caused by mutations in MAGI2. Kidney International, 96(3), 642- (2019) (0)
The PTEN y MMAC 1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase y Akt pathway (1998) (0)
Abstract B023: Prospective clinical genomic profiling of ewing sarcoma: ERF and FGFR1 mutations as recurrent secondary alterations of potential biological and therapeutic relevance (2022) (0)
The androgen receptor (2011) (0)
Androgen receptor modulator for the treatment of prostate cancer and associated diseases with the androgen receptor (2007) (0)
Abstract 2200: Multilineage plasticity in prostate cancer through expansion of stem-like luminal epithelial cells with elevated inflammatory signaling (2022) (0)
Extraordinary survivorship after colorectal liver metastasis resection to identify a distinct molecular profile associated with survival in an independent cohort of 965 patients. (2017) (0)
SYNERGISM OF IONIZING RADIATION AND GENE THERAPY WITH THE REPLICATION COMPETENT CN706 ADENOVIRUS IN THE LAPC-4 PROSTATE CANCER CELL LINE (1999) (0)
Mutations in the sti with the resistance against (2002) (0)
2043 Mechanisms of therapeutic synergy between radiation treatment and adenoviral gene therapy with the replication competent PSA-specific vector CN706 in the LAPC-4 and LnCaP prostate cancer cell lines (1999) (0)
Author Correction: Transcriptional regulation of a metastasis suppressor gene by Tip60 and β-catenin complexes (2022) (0)
- Abl: c-Abl protein-tyrosine kinase (vertebrates) (1995) (0)
ComprehensiveMutationalAnalysis andmRNA IsoformQuantificationofTP63 inNormaland NeoplasticHumanProstateCells (2009) (0)
Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis (2022) (0)
Abstract 2170:Rb1suppresses prostate cancer metastasis and lineage plasticity underlying castration resistance (2017) (0)
The authors reply [3] (2006) (0)
Abstract LB-056: TP53 and RB1 alterations promote reprogramming and antiandrogen resistance in advanced prostate cancer (2015) (0)
JAK2 and myeloproliferative neoplasms (2013) (0)
Publisher Correction: The long tail of oncogenic drivers in prostate cancer (2019) (0)
Abstract PR09: Macrophage promotion of anti-androgen resistance in prostate cancer bone disease (2022) (0)
TheBcr-Ablleukemia oncogeneactivates Junkinaseandrequires (1995) (0)

This paper list is powered by the following services:

Other Resources About Charles Sawyers

en.wikipedia.org

What Schools Are Affiliated With Charles Sawyers?

Charles Sawyers is affiliated with the following schools:

Charles Sawyers's Academic­Influence.com Rankings

Why Is Charles Sawyers Influential?

Charles Sawyers's Published Works

Published Works

Other Resources About Charles Sawyers

What Schools Are Affiliated With Charles Sawyers?

Image Attributions

Charles Sawyers's AcademicInfluence.com Rankings